Real-world study of the efficacy and safety of infliximab in the treat-ment of Crohn's disease with perianal fistula
10.12092/j.issn.1009-2501.2025.04.007
- VernacularTitle:英夫利昔单抗对肛周瘘管克罗恩病疗效及安全性的真实世界研究
- Author:
Jian WU
1
;
Xiaoli FANG
;
Ming LI
;
Hao CHEN
;
Jiarong GAO
Author Information
1. 安徽中医药大学第一附属医院药学部,合肥 230031,安徽
- Publication Type:Journal Article
- Keywords:
perianal fstulizing Crohn's disease;
in-fliximab;
clinical efficacy evaluation
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(5):640-647
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To evaluate the efficacy of inflix-imab in the maintenance of Perianal fstulizing Crohn's disease.METHODS:The clinical data of 24 patients with perianal fistula Crohn's disease(PFCD)treated with infliximab(IFX)in the Depart-ment of Anorectal Surgery of our hospital from No-vember 2020 to October 2023 were retrospectively collected.The clinical efficacy and safety were eval-uated by observing the clinical characteristics for 54 weeks.The fistula remission rate,clinical remis-sion rate,and endoscopic remission rate of pa-tients were calculated.The changes of laboratory indexes before and after treatment were recorded.Logistic regression was used to analyze the related factors of fistula remission.All adverse reactions oc-curred during IFX treatment were recorded.RE-SULTS:After 54 weeks of IFX treatment,the fistula remission rate,clinical remission rate,and endo-scopic remission rate were 37.5％,45.83％,and 33.33％,respectively.Fistula response at 14 weeks of treatment(OR=19.419,95％CI:1.267-297.559,P=0.033)was predictive factors for fistula remission at 54 weeks of treatment.The inflammatory index-es and nutritional indexes were significantly im-proved compared with those before treatment(P＜0.01).The scores of PDAI,CDAI and SES-CD were significantly different from those before treatment(P＜0.01).Five patients(20.83％)had adverse reac-tions,and the symptoms disappeared or improved after symptomatic treatment,and no patient had serious adverse reactions.CONCLUSION:IFX can ef-fectively promote the closure of PFCD fistula,im-prove the chronic inflammatory reaction of intesti-nal mucosa,alleviate clinical symptoms,and im-prove the quality of life of patients.IFX is effective and safe for PFCD maintenance treatment.
